|  |
April 2003 Stock Report (Revised)
| Company |
Close 04/25/03 |
% 52wk High |
% change from 04/30/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| GENOME THERAPEUTICS CORP |
$2.25 |
52% |
-43% |
$53 |
$34 |
$20 |
$16 |
204 |
$0.1 |
-$40.3 |
0.8 |
1.2 |
| HUMAN GENOME SCIENCES |
$10.91 |
58% |
-31% |
$1,406 |
$1,202 |
$204 |
$503 |
1010 |
$0.2 |
-$300.3 |
4.0 |
0.8 |
| INCYTE CORP |
$3.20 |
37% |
-61% |
$227 |
$376 |
-$149 |
$172 |
585 |
-$0.3 |
-$153.6 |
2.4 |
0.3 |
| MILLENNIUM PHARMACEUTICALS |
$10.82 |
54% |
-46% |
$3,163 |
$1,563 |
$1,600 |
$83 |
2079 |
$0.8 |
-$392.0 |
4.0 |
0.7 |
| MYRIAD GENETICS |
$10.98 |
42% |
-54% |
$297 |
$155 |
$141 |
$0 |
491 |
$0.3 |
-$27.6 |
5.6 |
1.1 |
| 1st Generation Genomics Average |
. |
48% |
-47% |
$1,029 |
$666 |
$363 |
$155 |
. |
$0.2 |
-$182.8 |
3.4 |
0.8 |
| 1st Generation Genomics Median |
. |
53% |
-44% |
$262 |
$266 |
$81 |
$50 |
. |
$0.2 |
-$97.0 |
3.2 |
0.9 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
Close 04/25/03 |
% 52wk High |
% change from 04/30/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| ACLARA BIOSCIENCES |
$2.14 |
74% |
-14% |
$76 |
$97 |
-$21 |
$1 |
170 |
-$0.1 |
-$44.8 |
2.2 |
0.3 |
| AFFYMETRIX |
$17.64 |
59% |
-30% |
$1,037 |
$353 |
$684 |
$370 |
905 |
$0.8 |
na |
na |
2.9 |
| CALIPER TECHNOLOGIES |
$3.56 |
31% |
-66% |
$88 |
$109 |
-$21 |
$0 |
132 |
-$0.2 |
-$37.5 |
2.9 |
0.3 |
| CEPHEID |
$3.55 |
54% |
0% |
$115 |
$9 |
$105 |
$2 |
143 |
$0.7 |
-$23.0 |
0.4 |
1.4 |
| CIPHERGEN BIOSYSTEMS |
$4.55 |
69% |
-26% |
$124 |
$30 |
$95 |
$0 |
229 |
$0.4 |
-$31.6 |
0.9 |
0.7 |
| COMBIMATRIX |
$2.24 |
45% |
na |
$51 |
na |
na |
na |
na |
na |
na |
na |
na |
| COMPUGEN |
$2.42 |
79% |
-10% |
$63 |
na |
na |
na |
176 |
na |
na |
na |
na |
| ILLUMINA |
$1.89 |
21% |
-78% |
$62 |
$38 |
$24 |
$25 |
179 |
$0.1 |
-$30.4 |
1.2 |
0.8 |
| NANOGEN |
$1.52 |
37% |
-54% |
$34 |
$30 |
$4 |
$0 |
194 |
$0.0 |
-$32.9 |
0.9 |
0.2 |
| ORCHID BIOSCIENCES |
$0.42 |
17% |
-82% |
$23 |
na |
na |
$4 |
595 |
na |
-$89.1 |
na |
0.1 |
| SEQUENOM |
$2.08 |
34% |
-65% |
$82 |
$72 |
$10 |
$6 |
272 |
$0.0 |
-$68.0 |
1.1 |
0.2 |
| TRANSGENOMIC |
$1.14 |
17% |
-81% |
$27 |
$9 |
$18 |
$0 |
308 |
$0.1 |
-$18.9 |
0.5 |
0.2 |
| Genomic Supply Average |
. |
45% |
-46% |
$149 |
$83 |
$100 |
$41 |
. |
$0.2 |
-$41.8 |
1.3 |
0.7 |
| Genomic Supply Median |
. |
45% |
-42% |
$63 |
$34 |
$14 |
$1 |
. |
$0.1 |
-$32.3 |
1.0 |
0.3 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
Close 04/25/03 |
% 52wk High |
% change from 04/30/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| APPLIED MOLECULAR EVOLUTION |
$3.04 |
41% |
-59% |
$63 |
$51 |
$11 |
$10 |
106 |
$0.1 |
-$15.9 |
3.2 |
0.4 |
| ARENA PHARMACEUTICALS |
$6.50 |
76% |
-20% |
$185 |
$196 |
-$11 |
$0 |
209 |
-$0.1 |
-$41.1 |
4.8 |
0.6 |
| CELERA GENOMICS GROUP |
$9.78 |
62% |
-37% |
$699 |
na |
na |
na |
na |
na |
na |
na |
na |
| CURAGEN CORP |
$4.63 |
42% |
-46% |
$229 |
$431 |
-$203 |
$150 |
454 |
-$0.4 |
-$79.5 |
5.4 |
0.5 |
| DECODE GENETICS |
$2.06 |
37% |
-63% |
$110 |
$102 |
$9 |
$0 |
592 |
$0.0 |
-$84.0 |
1.2 |
0.3 |
| DELTAGEN |
$0.42 |
7% |
-93% |
$16 |
$50 |
-$33 |
$2 |
356 |
-$0.1 |
-$88.0 |
0.6 |
0.1 |
| EXELIXIS |
$7.68 |
73% |
-22% |
$458 |
$216 |
$242 |
$59 |
550 |
$0.4 |
-$83.4 |
2.6 |
1.0 |
| GENAISSANCE PHARMACEUTICALS |
$1.28 |
49% |
-44% |
$29 |
$34 |
-$5 |
$5 |
104 |
$0.0 |
-$21.4 |
1.6 |
0.1 |
| GENE LOGIC |
$5.34 |
33% |
-66% |
$145 |
$167 |
-$22 |
$1 |
264 |
-$0.1 |
-$20.7 |
8.1 |
0.4 |
| GENENCOR INTERNATIONAL |
$10.60 |
85% |
0% |
$621 |
$171 |
$450 |
$85 |
1144 |
$0.4 |
na |
na |
1.2 |
| LARGE SCALE BIOLOGY |
$0.74 |
26% |
-72% |
$19 |
$27 |
-$9 |
$0 |
169 |
-$0.1 |
-$27.1 |
1.0 |
0.1 |
| LEXICON GENETICS |
$4.61 |
56% |
-42% |
$241 |
$114 |
$128 |
$0 |
507 |
$0.3 |
-$67.2 |
1.7 |
0.7 |
| LYNX THERAPEUTICS |
$2.28 |
19% |
-78% |
$11 |
$13 |
-$2 |
$1 |
182 |
$0.0 |
-$13.1 |
1.0 |
0.1 |
| MAXYGEN |
$8.07 |
66% |
-12% |
$279 |
$229 |
$51 |
$0 |
308 |
$0.2 |
-$29.2 |
7.8 |
0.7 |
| NUVELO |
$1.28 |
31% |
-69% |
$81 |
$4 |
$76 |
$0 |
224 |
$0.3 |
-$5.8 |
0.7 |
0.1 |
| PARADIGM GENETICS |
$0.83 |
44% |
-54% |
$27 |
$9 |
$17 |
$4 |
253 |
$0.1 |
-$15.7 |
0.6 |
0.3 |
| RIGEL PHARMACEUTICALS |
$0.75 |
15% |
-84% |
$232 |
$37 |
$195 |
$0 |
147 |
$1.3 |
-$40.6 |
0.9 |
1.7 |
| SANGAMO BIOSCIENCES |
$2.60 |
30% |
-70% |
$64 |
$52 |
$12 |
$0 |
90 |
$0.1 |
-$83.8 |
0.6 |
0.5 |
| ZYMOGENETICS |
$9.98 |
82% |
-15% |
$458 |
$215 |
$243 |
$0 |
309 |
$0.8 |
-$57.9 |
3.7 |
1.1 |
| Genomic Targets Average |
. |
46% |
-50% |
$209 |
$118 |
$64 |
$18 |
. |
$0.2 |
-$45.6 |
2.7 |
0.5 |
| Genomic Targets Median |
. |
43% |
-50% |
$128 |
$52 |
$11 |
$1 |
. |
$0.1 |
-$34.9 |
1.4 |
0.5 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
Close 04/25/03 |
% 52wk High |
% change from 04/30/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| EDEN BIOSCIENCES |
$1.72 |
51% |
-41% |
$42 |
$35 |
$7 |
$0 |
98 |
$0.1 |
-$18.6 |
1.9 |
0.3 |
| EMBREX |
$8.11 |
32% |
-64% |
$66 |
$8 |
$58 |
$0 |
221 |
$0.3 |
na |
na |
1.1 |
| IDEXX LABORATORIES |
$36.19 |
95% |
27% |
$1,231 |
$128 |
$1,104 |
$0 |
2170 |
$0.5 |
na |
na |
3.7 |
| IMMUCELL CORP |
$2.00 |
64% |
-35% |
$6 |
$4 |
$2 |
$0 |
11 |
$0.2 |
-$3.6 |
1.2 |
0.1 |
| NEOGEN |
$15.05 |
95% |
2% |
$92 |
$7 |
$85 |
$0 |
265 |
$0.3 |
na |
na |
3.8 |
| Agbio/enviro. Average |
. |
67% |
-22% |
$288 |
$36 |
$251 |
$0 |
. |
$0.3 |
-$11.1 |
1.5 |
1.8 |
| Agbio/enviro. Median |
. |
79% |
-16% |
$54 |
$7 |
$33 |
$0 |
. |
$0.3 |
-$3.6 |
1.2 |
1.0 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
Close 04/25/03 |
% 52wk High |
% change from 04/30/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| ALEXION PHARMACEUTICALS |
$12.91 |
62% |
-30% |
$235 |
$283 |
-$48 |
$124 |
172 |
-$0.3 |
-$86.6 |
3.3 |
0.6 |
| ATHEROGENICS |
$9.11 |
84% |
13% |
$332 |
$41 |
$291 |
$0 |
79 |
$3.7 |
-$27.7 |
1.5 |
2.7 |
| AUTOIMMUNE |
$0.95 |
83% |
2% |
$16 |
$10 |
$6 |
$0 |
2 |
$2.9 |
-$1.0 |
10.4 |
0.1 |
| CONNETICS CORP |
$15.75 |
90% |
31% |
$495 |
$33 |
$461 |
$0 |
190 |
$2.4 |
-$22.4 |
1.5 |
2.9 |
| CORTECH |
$2.60 |
69% |
-30% |
$9 |
$0 |
$9 |
$0 |
na |
na |
na |
na |
94.0 |
| CYPRESS BIOSCIENCE |
$2.27 |
62% |
-34% |
$30 |
$14 |
$16 |
$0 |
9 |
$1.8 |
-$7.2 |
1.9 |
0.3 |
| ICOS CORP |
$25.13 |
62% |
-2% |
$1,562 |
$200 |
$1,362 |
$0 |
525 |
$2.6 |
-$136.0 |
1.5 |
2.0 |
| INKINE PHARMACEUTICAL CO |
$2.30 |
92% |
54% |
$87 |
$7 |
$79 |
$0 |
12 |
$6.6 |
-$5.9 |
1.3 |
1.5 |
| LA JOLLA PHARMACEUTICAL CO |
$1.92 |
22% |
-74% |
$82 |
$65 |
$16 |
$0 |
118 |
$0.1 |
-$42.7 |
1.5 |
0.4 |
| PROTEIN DESIGN LABS |
$9.32 |
50% |
-48% |
$831 |
$624 |
$207 |
$159 |
363 |
$0.6 |
-$32.0 |
19.5 |
1.3 |
| TANOX |
$13.11 |
93% |
10% |
$574 |
$235 |
$339 |
$5 |
114 |
$3.0 |
-$30.6 |
7.7 |
1.8 |
| Autoimmune Average |
. |
70% |
-10% |
$387 |
$138 |
$249 |
$26 |
. |
$2.3 |
-$39.2 |
5.0 |
9.8 |
| Autoimmune Median |
. |
76% |
0% |
$161 |
$37 |
$48 |
$0 |
. |
$2.4 |
-$27.7 |
1.5 |
1.4 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
Close 04/25/03 |
% 52wk High |
% change from 04/30/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| ALLOS THERAPEUTICS |
$1.95 |
20% |
-75% |
$50 |
$60 |
-$10 |
$0 |
61 |
-$0.2 |
-$21.2 |
2.8 |
0.3 |
| ANTIGENICS |
$9.25 |
74% |
-21% |
$364 |
$70 |
$294 |
$0 |
208 |
$1.4 |
-$54.2 |
1.3 |
1.3 |
| APHTON CORP |
$3.63 |
31% |
-63% |
$90 |
$9 |
$81 |
$0 |
50 |
$1.6 |
-$43.7 |
0.2 |
0.7 |
| ARIAD PHARMACEUTICALS |
$2.19 |
40% |
-55% |
$76 |
$28 |
$48 |
$6 |
69 |
$0.7 |
-$31.3 |
0.9 |
0.5 |
| AVAX TECHNOLOGIES |
$0.26 |
38% |
-46% |
$5 |
$6 |
-$1 |
$0 |
43 |
$0.0 |
-$10.4 |
0.6 |
0.1 |
| AVI BIOPHARMA |
$7.05 |
92% |
-2% |
$187 |
$22 |
$165 |
$0 |
85 |
$1.9 |
-$28.2 |
0.8 |
1.4 |
| BIOMIRA |
$1.20 |
29% |
-53% |
$64 |
$60 |
$4 |
$0 |
158 |
$0.0 |
-$12.7 |
4.7 |
1.0 |
| BOSTON LIFE SCIENCES |
$1.39 |
70% |
-23% |
$45 |
$0 |
$45 |
$0 |
14 |
$3.2 |
na |
na |
na |
| BRITISH BIOTECH PLC |
$2.20 |
29% |
-69% |
$37 |
$60 |
-$23 |
$5 |
96 |
-$0.2 |
-$59.4 |
1.0 |
0.1 |
| CELGENE CORP |
$27.88 |
96% |
41% |
$2,243 |
$289 |
$1,954 |
$0 |
383 |
$5.1 |
-$4.1 |
69.7 |
4.1 |
| CELL PATHWAYS |
$1.10 |
29% |
-68% |
$43 |
$17 |
$26 |
$0 |
77 |
$0.3 |
-$18.9 |
0.9 |
0.3 |
| CELL THERAPEUTICS |
$8.43 |
66% |
-32% |
$279 |
$169 |
$110 |
$0 |
238 |
$0.5 |
-$121.6 |
1.4 |
0.7 |
| CORIXA CORP |
$6.77 |
73% |
23% |
$340 |
$89 |
$252 |
$7 |
366 |
$0.7 |
-$77.8 |
1.1 |
0.3 |
| CYTOGEN CORP |
$4.00 |
22% |
-76% |
$35 |
$16 |
$19 |
$3 |
74 |
$0.3 |
-$15.9 |
1.0 |
0.1 |
| DENDREON |
$4.87 |
68% |
12% |
$131 |
$55 |
$76 |
$0 |
144 |
$0.5 |
-$20.8 |
2.6 |
0.8 |
| DUSA PHARMACEUTICALS |
$2.03 |
48% |
-49% |
$28 |
$53 |
-$25 |
$2 |
43 |
-$0.6 |
-$14.8 |
3.6 |
0.3 |
| ENTREMED |
$2.52 |
31% |
-68% |
$62 |
$5 |
$57 |
$3 |
112 |
$0.5 |
-$47.0 |
0.1 |
0.3 |
| EXEGENICS |
$0.52 |
34% |
-65% |
$8 |
$20 |
-$12 |
$0 |
29 |
-$0.4 |
-$10.7 |
1.9 |
0.1 |
| GENAERA |
$0.33 |
10% |
-85% |
$12 |
$12 |
$0 |
$0 |
57 |
$0.0 |
-$11.9 |
1.0 |
0.1 |
| GENTA |
$7.40 |
45% |
-45% |
$546 |
$127 |
$419 |
$10 |
60 |
$7.0 |
-$60.4 |
2.1 |
1.7 |
| GENZYME MOLECULAR ONCOLOGY |
$2.36 |
52% |
-39% |
$40 |
na |
na |
na |
na |
na |
na |
na |
na |
| GERON CORP |
$4.85 |
61% |
-39% |
$121 |
$48 |
$73 |
$16 |
52 |
$1.4 |
-$28.9 |
1.6 |
0.5 |
| ILEX ONCOLOGY |
$10.91 |
61% |
-33% |
$355 |
$149 |
$206 |
$0 |
310 |
$0.7 |
-$41.6 |
3.6 |
0.8 |
| IMCLONE SYSTEMS |
$16.48 |
85% |
2% |
$1,213 |
$293 |
$920 |
$242 |
399 |
$2.3 |
-$168.0 |
1.7 |
3.5 |
| IMMUNOGEN |
$2.99 |
35% |
-64% |
$129 |
$119 |
$10 |
$0 |
1618 |
$0.0 |
na |
na |
0.1 |
| IMMUNOMEDICS |
$3.79 |
25% |
-71% |
$189 |
$34 |
$155 |
$0 |
94 |
$1.7 |
-$7.1 |
4.7 |
1.2 |
| MAXIM PHARMACEUTICALS |
$3.55 |
68% |
-27% |
$83 |
$97 |
-$15 |
$1 |
115 |
-$0.1 |
-$37.3 |
2.6 |
0.2 |
| MEDAREX |
$4.15 |
39% |
-59% |
$321 |
$370 |
-$49 |
$175 |
297 |
-$0.2 |
-$216.5 |
1.7 |
0.5 |
| NAPRO BIOTHERAPEUTICS |
$0.60 |
6% |
-91% |
$18 |
$12 |
$6 |
$25 |
189 |
$0.0 |
-$15.8 |
0.7 |
0.2 |
| NEOPHARM |
$13.84 |
85% |
-8% |
$226 |
$102 |
$124 |
$0 |
72 |
$1.7 |
-$41.1 |
2.5 |
1.3 |
| NEORX CORP |
$3.00 |
72% |
20% |
$81 |
$12 |
$68 |
$5 |
118 |
$0.6 |
-$46.0 |
0.3 |
0.4 |
| OSI PHARMACEUTICALS |
$19.24 |
57% |
-40% |
$701 |
$434 |
$267 |
$0 |
429 |
$0.6 |
-$120.4 |
3.6 |
1.0 |
| OXIGENE |
$1.67 |
52% |
-2% |
$21 |
$14 |
$7 |
$0 |
14 |
$0.5 |
-$6.7 |
2.1 |
0.3 |
| PRAECIS PHARMACEUTICALS |
$4.35 |
93% |
22% |
$225 |
$209 |
$16 |
$33 |
127 |
$0.1 |
-$22.3 |
9.4 |
0.6 |
| PROGENICS PHARMACEUTICALS |
$8.79 |
57% |
-37% |
$112 |
$42 |
$70 |
$0 |
80 |
$0.9 |
-$25.6 |
1.6 |
1.2 |
| QLT PHOTOTHERAPEUTICS |
$11.70 |
77% |
-14% |
$802 |
$177 |
$625 |
$0 |
285 |
$2.2 |
-$33.3 |
5.3 |
2.5 |
| SCICLONE PHARMACEUTICALS |
$6.47 |
75% |
73% |
$242 |
$25 |
$218 |
$6 |
84 |
$2.6 |
-$6.7 |
3.7 |
1.6 |
| SEATTLE GENETICS |
$2.45 |
40% |
-55% |
$75 |
$31 |
$44 |
$0 |
69 |
$0.6 |
-$20.4 |
1.5 |
0.7 |
| SPECTRUM PHARMACEUTICALS |
$2.75 |
5% |
-84% |
$8 |
na |
na |
$0 |
96 |
na |
-$9.4 |
na |
0.1 |
| SUPERGEN |
$3.39 |
43% |
-38% |
$112 |
$27 |
$84 |
$0 |
115 |
$0.7 |
-$80.4 |
0.3 |
0.4 |
| XENOVA GROUP PLC |
$2.35 |
24% |
-74% |
$33 |
$29 |
$4 |
$0 |
134 |
$0.0 |
-$13.9 |
2.1 |
1.1 |
| Cancer Average |
. |
50% |
-36% |
$238 |
$87 |
$162 |
$13 |
. |
$1.0 |
-$42.3 |
4.0 |
0.8 |
| Cancer Median |
. |
51% |
-39% |
$101 |
$45 |
$62 |
$0 |
. |
$0.6 |
-$28.2 |
1.7 |
0.7 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
Close 04/25/03 |
% 52wk High |
% change from 04/30/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| CORVAS INTERNATIONAL |
$2.00 |
62% |
-36% |
$55 |
$71 |
-$16 |
$12 |
95 |
-$0.2 |
-$26.2 |
2.7 |
0.2 |
| CV THERAPEUTICS |
$18.91 |
62% |
-35% |
$521 |
$420 |
$101 |
$196 |
222 |
$0.5 |
-$99.3 |
4.2 |
1.0 |
| MEDICINES COMPANY |
$20.68 |
100% |
111% |
$844 |
$44 |
$801 |
$0 |
147 |
$5.4 |
-$39.3 |
1.1 |
2.4 |
| QUESTCOR PHARMACEUTICALS |
$0.77 |
41% |
-52% |
$30 |
$9 |
$20 |
$3 |
38 |
$0.5 |
-$4.0 |
2.3 |
0.4 |
| SCIOS |
$44.92 |
100% |
45% |
$2,115 |
$66 |
$2,048 |
$161 |
425 |
$4.8 |
-$87.3 |
0.8 |
3.7 |
| TEXAS BIOTECHNOLOGY CORP |
$1.76 |
32% |
-66% |
$77 |
$47 |
$30 |
$0 |
110 |
$0.3 |
-$23.4 |
2.0 |
0.4 |
| Cardiovascular Average |
. |
66% |
-6% |
$607 |
$110 |
$497 |
$62 |
. |
$1.9 |
-$46.6 |
2.2 |
1.3 |
| Cardiovascular Median |
. |
62% |
-35% |
$77 |
$47 |
$30 |
$3 |
. |
$0.5 |
-$26.2 |
2.0 |
1.0 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
Close 04/25/03 |
% 52wk High |
% change from 04/30/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| ALBANY MOLECULAR RESEARCH |
$11.06 |
45% |
-54% |
$354 |
$121 |
$233 |
$5 |
532 |
$0.4 |
na |
na |
1.9 |
| ARGONAUT TECHNOLOGIES |
$0.84 |
33% |
-64% |
$17 |
$29 |
-$12 |
$0 |
154 |
-$0.1 |
-$21.4 |
1.3 |
0.1 |
| ARQULE |
$3.81 |
38% |
-60% |
$89 |
$83 |
$6 |
$8 |
385 |
$0.0 |
-$21.9 |
3.8 |
0.4 |
| ARRAY BIOPHARMA |
$2.26 |
19% |
-77% |
$63 |
$47 |
$16 |
$0 |
245 |
$0.1 |
-$11.6 |
4.0 |
0.5 |
| BIOCRYST PHARMACEUTICALS |
$1.91 |
45% |
-52% |
$34 |
$27 |
$7 |
$0 |
77 |
$0.1 |
-$13.7 |
2.0 |
0.3 |
| DISCOVERY PARTNERS |
$3.25 |
49% |
-34% |
$79 |
$70 |
$9 |
$0 |
225 |
$0.0 |
-$3.2 |
21.6 |
0.4 |
| KOSAN BIOSCIENCES |
$6.97 |
75% |
-13% |
$178 |
$53 |
$124 |
$0 |
68 |
$1.8 |
-$12.7 |
4.2 |
1.2 |
| PHARMACOPEIA |
$8.90 |
71% |
-23% |
$210 |
$142 |
$68 |
$0 |
800 |
$0.1 |
-$25.3 |
5.6 |
0.7 |
| SYMYX TECHNOLOGIES |
$15.00 |
72% |
-24% |
$465 |
$118 |
$347 |
$0 |
213 |
$1.6 |
na |
na |
3.0 |
| VERTEX PHARMACEUTICALS |
$11.68 |
49% |
-45% |
$894 |
$651 |
$242 |
$315 |
1000 |
$0.2 |
-$133.8 |
4.9 |
1.1 |
| Chemistry Average |
. |
50% |
-45% |
$238 |
$134 |
$104 |
$33 |
. |
$0.4 |
-$30.4 |
5.9 |
1.0 |
| Chemistry Median |
. |
49% |
-45% |
$89 |
$70 |
$16 |
$0 |
. |
$0.1 |
-$13.7 |
4.0 |
0.7 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
Close 04/25/03 |
% 52wk High |
% change from 04/30/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| ADOLOR |
$13.65 |
85% |
-1% |
$430 |
$154 |
$276 |
$0 |
124 |
$2.2 |
-$48.2 |
3.2 |
1.7 |
| CEPHALON |
$39.97 |
66% |
-32% |
$2,204 |
$637 |
$1,568 |
$871 |
1127 |
$1.4 |
na |
na |
2.2 |
| DOV PHARMACEUTICALS |
$5.99 |
65% |
na |
$87 |
$64 |
$22 |
$14 |
25 |
$0.9 |
-$10.4 |
6.2 |
1.1 |
| GUILFORD PHARMACEUTICALS |
$4.99 |
59% |
-35% |
$149 |
$96 |
$53 |
$4 |
289 |
$0.2 |
-$58.3 |
1.6 |
0.4 |
| INDEVUS PHARMACEUTICALS |
$3.87 |
51% |
-43% |
$181 |
$36 |
$145 |
$0 |
24 |
$6.1 |
-$21.7 |
1.7 |
0.6 |
| NEUROBIOLOGICAL TECHNOLOGIES |
$7.27 |
91% |
91% |
$131 |
$6 |
$125 |
$0 |
11 |
$11.3 |
-$5.3 |
1.1 |
2.9 |
| NEUROCRINE BIOSCIENCES |
$44.70 |
89% |
36% |
$1,373 |
$245 |
$1,128 |
$0 |
276 |
$4.1 |
-$155.1 |
1.6 |
3.2 |
| NYMOX PHARMACEUTICAL |
$3.60 |
63% |
-3% |
$83 |
$1 |
$82 |
na |
60 |
$1.4 |
na |
na |
na |
| PAIN THERAPEUTICS |
$3.05 |
30% |
-70% |
$83 |
$54 |
$29 |
$0 |
33 |
$0.9 |
-$12.2 |
4.4 |
0.8 |
| PHARMOS CORP |
$0.88 |
57% |
-14% |
$54 |
$25 |
$29 |
$0 |
70 |
$0.4 |
-$21.8 |
1.2 |
0.5 |
| STEMCELLS |
$0.77 |
34% |
-63% |
$21 |
$7 |
$14 |
$0 |
33 |
$0.4 |
-$10.9 |
0.6 |
0.1 |
| TITAN PHARMACEUTICALS |
$1.59 |
25% |
-73% |
$44 |
$81 |
-$37 |
$0 |
58 |
-$0.6 |
-$29.2 |
2.8 |
0.2 |
| CNS Average |
. |
60% |
-19% |
$403 |
$117 |
$286 |
$81 |
. |
$2.4 |
-$37.3 |
2.4 |
1.3 |
| CNS Median |
. |
63% |
-23% |
$87 |
$54 |
$53 |
$0 |
. |
$1.0 |
-$21.7 |
1.6 |
0.9 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
Close 04/25/03 |
% 52wk High |
% change from 04/30/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| BIOSOURCE INTERNATIONAL |
$5.00 |
71% |
-17% |
$48 |
$6 |
$42 |
$0 |
257 |
$0.2 |
na |
na |
1.1 |
| GTC BIOTHERAPEUTICS |
$1.39 |
49% |
-50% |
$39 |
$66 |
-$27 |
$13 |
168 |
-$0.2 |
-$27.9 |
2.4 |
0.2 |
| HARVARD BIOSCIENCE |
$3.11 |
38% |
-60% |
$93 |
$26 |
$67 |
$0 |
131 |
$0.5 |
-$0.3 |
80.7 |
0.6 |
| ICON PLC |
$24.50 |
75% |
-19% |
$289 |
na |
na |
na |
1637 |
na |
na |
na |
na |
| INVITROGEN CORP |
$31.45 |
83% |
-9% |
$1,573 |
$731 |
$841 |
$675 |
2744 |
$0.3 |
na |
na |
0.8 |
| MOLECULAR DEVICES CORP |
$11.20 |
57% |
-37% |
$172 |
$51 |
$121 |
$0 |
370 |
$0.3 |
na |
na |
0.9 |
| NEOSE TECHNOLOGIES |
$7.17 |
26% |
-70% |
$123 |
$43 |
$80 |
$4 |
111 |
$0.7 |
-$23.8 |
1.8 |
0.7 |
| PARAXEL INTERNATIONAL |
$12.39 |
78% |
-20% |
$314 |
$80 |
$234 |
$1 |
4930 |
$0.0 |
na |
na |
1.9 |
| PHARMACEUTICAL PRODUCT DEVELOP |
$25.53 |
79% |
1% |
$1,419 |
$181 |
$1,238 |
$7 |
4300 |
$0.3 |
na |
na |
5.3 |
| QIAGEN NV |
$5.93 |
36% |
-55% |
$862 |
$30 |
$832 |
$0 |
1557 |
$0.5 |
na |
na |
17.4 |
| QUINTILES TRANSNATIONAL CORP |
$14.00 |
92% |
-1% |
$1,650 |
$672 |
$978 |
$8 |
15548 |
$0.1 |
na |
na |
1.9 |
| CRO/Service/Supply Average |
. |
62% |
-31% |
$598 |
$189 |
$441 |
$71 |
. |
$0.3 |
-$17.3 |
28.3 |
3.1 |
| CRO/Service/Supply Median |
. |
73% |
-20% |
$231 |
$51 |
$121 |
$1 |
. |
$0.3 |
-$12.1 |
2.1 |
1.0 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
Close 04/25/03 |
% 52wk High |
% change from 04/30/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| ABGENIX |
$9.31 |
60% |
-34% |
$817 |
$464 |
$353 |
$200 |
324 |
$1.1 |
-$135.4 |
3.4 |
0.8 |
| AEROGEN |
$0.19 |
10% |
-89% |
$4 |
$15 |
-$11 |
$0 |
140 |
-$0.1 |
-$22.7 |
0.7 |
0.0 |
| ALKERMES |
$10.00 |
46% |
-50% |
$645 |
$158 |
$487 |
$172 |
520 |
$0.9 |
na |
na |
1.4 |
| ANDRX |
$15.44 |
32% |
-66% |
$1,108 |
$157 |
$951 |
$0 |
1837 |
$0.5 |
-$132.3 |
1.2 |
2.3 |
| ARADIGM CORP |
$0.99 |
22% |
-74% |
$45 |
$35 |
$9 |
$0 |
307 |
$0.0 |
-$41.1 |
0.9 |
0.2 |
| ATRIX LABORATORIES |
$15.78 |
63% |
-34% |
$324 |
$112 |
$212 |
$0 |
167 |
$1.3 |
-$21.3 |
5.3 |
1.3 |
| BIODELIVERY SCIENCES |
$2.65 |
70% |
na |
$19 |
$6 |
$12 |
$0 |
8 |
$1.5 |
-$5.7 |
1.1 |
1.4 |
| CIMA LABS |
$22.86 |
78% |
14% |
$327 |
$73 |
$254 |
$0 |
171 |
$1.5 |
na |
na |
1.4 |
| DEPOMED |
$2.65 |
50% |
-49% |
$44 |
$9 |
$35 |
$0 |
40 |
$0.9 |
-$35.4 |
0.3 |
0.6 |
| DOR BIOPHARMA |
$0.87 |
51% |
-9% |
$23 |
$4 |
$19 |
$0 |
22 |
$0.9 |
-$2.5 |
1.6 |
0.3 |
| DURECT |
$2.67 |
29% |
-68% |
$135 |
$43 |
$92 |
$1 |
6 |
$15.3 |
-$33.8 |
1.3 |
0.7 |
| EMISPHERE TECHNOLOGIES |
$2.81 |
18% |
-82% |
$50 |
$18 |
$32 |
$32 |
241 |
$0.1 |
-$52.1 |
0.3 |
0.2 |
| ENZON PHARMACEUTICALS |
$13.24 |
34% |
-64% |
$575 |
$120 |
$455 |
$0 |
127 |
$3.6 |
-$61.0 |
2.0 |
2.1 |
| FLAMEL TECHNOLOGIES SA |
$9.60 |
97% |
373% |
$156 |
$13 |
$143 |
$2 |
137 |
$1.0 |
-$8.9 |
1.5 |
3.0 |
| GENEREX BIOTECHNOLOGY |
$0.88 |
17% |
-75% |
$18 |
$14 |
$4 |
$1 |
23 |
$0.2 |
-$18.3 |
0.8 |
0.2 |
| GENETRONICS BIOMEDICAL LTD |
$0.28 |
42% |
-38% |
$14 |
$2 |
$12 |
$0 |
27 |
$0.4 |
-$5.6 |
0.4 |
0.3 |
| KOS PHARMACEUTICALS |
$18.02 |
69% |
-31% |
$375 |
$20 |
$356 |
$0 |
726 |
$0.5 |
na |
na |
1.7 |
| MACROCHEM CORP |
$1.15 |
38% |
-48% |
$32 |
$10 |
$22 |
$0 |
32 |
$0.7 |
-$6.1 |
1.7 |
0.4 |
| MEDICIS PHARMACEUTICAL |
$56.87 |
100% |
6% |
$1,540 |
$579 |
$961 |
$400 |
279 |
$3.4 |
na |
na |
3.5 |
| NASTECH PHARMACEUTICAL |
$7.90 |
48% |
-35% |
$81 |
$14 |
$66 |
$5 |
72 |
$0.9 |
-$13.6 |
1.0 |
1.3 |
| NEKTAR THERAPEUTICS |
$8.09 |
81% |
2% |
$450 |
$314 |
$137 |
$299 |
694 |
$0.2 |
-$106.1 |
3.0 |
0.6 |
| NOVAVAX |
$4.05 |
67% |
-19% |
$120 |
$8 |
$113 |
$40 |
173 |
$0.7 |
-$26.9 |
0.3 |
1.2 |
| NOVEN PHARMACEUTICALS |
$14.45 |
53% |
-28% |
$326 |
$60 |
$266 |
$0 |
252 |
$1.1 |
na |
na |
4.2 |
| SEPRACOR |
$19.00 |
99% |
50% |
$1,603 |
$553 |
$1,049 |
$999 |
930 |
$1.1 |
-$94.4 |
5.9 |
2.0 |
| SHEFFIELD PHARMACEUTICALS |
$0.25 |
12% |
-87% |
$7 |
$0 |
$7 |
$12 |
16 |
$0.4 |
-$5.2 |
0.1 |
0.1 |
| Delivery Average |
. |
51% |
-22% |
$353 |
$112 |
$241 |
$86 |
. |
$1.5 |
-$41.4 |
1.6 |
1.2 |
| Delivery Median |
. |
51% |
-35% |
$127 |
$19 |
$102 |
$1 |
. |
$0.9 |
-$22.7 |
1.1 |
1.1 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
Close 04/25/03 |
% 52wk High |
% change from 04/30/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| ADVANCED MAGNETICS |
$4.25 |
80% |
10% |
$28 |
$17 |
$11 |
$0 |
24 |
$0.5 |
-$1.5 |
11.6 |
0.6 |
| BIOSITE |
$41.55 |
94% |
33% |
$621 |
$68 |
$552 |
$5 |
351 |
$1.6 |
na |
na |
8.0 |
| CHOLESTECH CORP |
$10.30 |
51% |
-43% |
$140 |
$16 |
$124 |
$0 |
220 |
$0.6 |
-$14.8 |
1.1 |
1.7 |
| DIAGNOSTIC PRODUCTS CORP |
$39.28 |
74% |
-18% |
$1,124 |
$43 |
$1,081 |
$0 |
1955 |
$0.6 |
na |
na |
19.3 |
| DIGENE CORP |
$18.64 |
76% |
-18% |
$338 |
$32 |
$306 |
$3 |
243 |
$1.3 |
-$5.4 |
6.0 |
2.9 |
| ENZO BIOCHEM |
$14.34 |
73% |
-21% |
$408 |
$73 |
$335 |
$0 |
231 |
$1.5 |
na |
na |
2.5 |
| EPIX MEDICAL |
$9.65 |
66% |
-27% |
$165 |
$36 |
$129 |
$0 |
88 |
$1.5 |
-$22.4 |
1.6 |
1.4 |
| EXACT SCIENCES |
$9.67 |
56% |
-18% |
$184 |
$44 |
$141 |
$0 |
75 |
$1.9 |
na |
na |
1.6 |
| GEN-PROBE |
$25.45 |
89% |
na |
$606 |
$107 |
$499 |
$0 |
186 |
$2.7 |
na |
na |
3.2 |
| HYCOR BIOMEDICAL |
$2.64 |
64% |
0% |
$21 |
$6 |
$16 |
$1 |
149 |
$0.1 |
na |
na |
1.6 |
| IGEN INTERNATIONAL |
$34.69 |
76% |
-16% |
$824 |
$42 |
$782 |
$45 |
370 |
$2.1 |
-$17.2 |
2.4 |
3.4 |
| IMMUCOR |
$19.10 |
74% |
98% |
$244 |
$2 |
$242 |
$0 |
30 |
$8.1 |
na |
na |
26.4 |
| LUMINEX |
$5.85 |
72% |
-9% |
$173 |
$40 |
$133 |
$0 |
183 |
$0.7 |
-$22.1 |
1.8 |
1.4 |
| MARTEK BIOSCIENCES CORP |
$32.11 |
98% |
11% |
$756 |
$22 |
$734 |
$0 |
198 |
$3.7 |
na |
na |
3.2 |
| MATRITECH |
$1.89 |
58% |
-17% |
$61 |
$3 |
$58 |
$0 |
44 |
$1.3 |
-$8.5 |
0.3 |
0.8 |
| MERIDIAN BIOSCIENCE |
$8.95 |
99% |
19% |
$131 |
$4 |
$127 |
$24 |
350 |
$0.4 |
na |
na |
5.5 |
| ORASURE |
$7.01 |
81% |
-4% |
$269 |
$13 |
$256 |
$3 |
221 |
$1.2 |
-$1.5 |
8.6 |
1.8 |
| OSTEX INTERNATIONAL |
$1.77 |
71% |
-21% |
$22 |
$1 |
$21 |
$1 |
46 |
$0.5 |
-$4.5 |
0.2 |
0.5 |
| QUIDEL CORP |
$4.65 |
66% |
-31% |
$134 |
$5 |
$130 |
$0 |
336 |
$0.4 |
-$4.8 |
1.0 |
1.0 |
| SONUS PHARMACEUTICALS |
$3.55 |
66% |
-18% |
$49 |
$16 |
$32 |
$0 |
37 |
$0.9 |
-$9.6 |
1.7 |
0.9 |
| TRINITY BIOTECH PLC |
$2.72 |
96% |
80% |
$110 |
$1 |
$109 |
$0 |
332 |
$0.3 |
na |
na |
5.1 |
| Diagnostic/imag. Average |
. |
75% |
0% |
$305 |
$28 |
$277 |
$4 |
. |
$1.5 |
-$10.2 |
3.3 |
4.4 |
| Diagnostic/imag. Median |
. |
74% |
-16% |
$169 |
$17 |
$131 |
$0 |
. |
$1.1 |
-$6.9 |
1.7 |
1.7 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
Close 04/25/03 |
% 52wk High |
% change from 04/30/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| AASTROM BIOSCIENCES |
$0.40 |
56% |
-43% |
$21 |
$7 |
$14 |
$0 |
44 |
$0.3 |
-$9.1 |
0.7 |
0.2 |
| AVIGEN |
$2.84 |
25% |
-74% |
$57 |
$125 |
-$68 |
$0 |
143 |
-$0.5 |
-$28.4 |
4.4 |
0.2 |
| CELL GENESYS |
$8.68 |
57% |
-39% |
$321 |
$226 |
$95 |
$0 |
262 |
$0.4 |
-$50.8 |
4.4 |
1.1 |
| CORAUTUS GENETICS |
$1.55 |
25% |
-72% |
$5 |
$8 |
-$2 |
$0 |
43 |
-$0.1 |
-$10.8 |
0.7 |
0.1 |
| DIACRIN |
$3.46 |
100% |
112% |
$62 |
$40 |
$22 |
$0 |
30 |
$0.7 |
-$6.1 |
6.5 |
0.6 |
| GENVEC |
$2.68 |
61% |
-12% |
$61 |
$21 |
$40 |
$5 |
83 |
$0.5 |
-$27.7 |
0.7 |
0.5 |
| INTROGEN |
$2.60 |
53% |
-40% |
$56 |
$31 |
$25 |
$7 |
77 |
$0.3 |
-$22.8 |
1.4 |
0.6 |
| SIRNA THERAPEUTICS |
$4.38 |
43% |
-48% |
$21 |
$15 |
$6 |
$5 |
130 |
$0.0 |
-$27.3 |
0.6 |
0.1 |
| TARGETED GENETICS CORP |
$0.71 |
39% |
-59% |
$36 |
$17 |
$19 |
$23 |
173 |
$0.1 |
-$19.3 |
0.9 |
0.2 |
| TRANSGENE SA |
$1.15 |
42% |
-53% |
$35 |
na |
na |
$0 |
318 |
na |
na |
na |
na |
| TRANSKARYOTIC THERAPIES |
$6.04 |
14% |
-85% |
$211 |
$288 |
-$78 |
$0 |
376 |
-$0.2 |
-$83.6 |
3.5 |
0.3 |
| VALENTIS |
$2.70 |
3% |
-96% |
$3 |
$8 |
-$5 |
$0 |
58 |
-$0.1 |
-$20.5 |
0.4 |
0.0 |
| VICAL |
$3.30 |
35% |
-65% |
$66 |
$120 |
-$53 |
$0 |
152 |
-$0.4 |
-$40.9 |
2.9 |
0.3 |
| Gene therapy Average |
. |
43% |
-44% |
$73 |
$75 |
$1 |
$3 |
. |
$0.1 |
-$29.0 |
2.3 |
0.4 |
| Gene therapy Median |
. |
43% |
-50% |
$46 |
$21 |
$6 |
$0 |
. |
$0.1 |
-$22.8 |
1.0 |
0.3 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
Close 04/25/03 |
% 52wk High |
% change from 04/30/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| AVANT IMMUNOTHERAPEUTICS |
$1.45 |
74% |
-18% |
$88 |
$26 |
$61 |
$0 |
71 |
$0.9 |
-$1.1 |
23.8 |
0.4 |
| CUBIST PHARMACEUTICALS |
$8.13 |
48% |
-42% |
$241 |
$147 |
$93 |
$209 |
180 |
$0.5 |
-$68.0 |
2.2 |
1.0 |
| EPIMMUNE |
$1.04 |
42% |
-55% |
$13 |
$12 |
$1 |
$0 |
52 |
$0.0 |
-$6.0 |
2.0 |
0.1 |
| GENELABS TECHNOLOGIES |
$1.57 |
44% |
107% |
$84 |
$12 |
$72 |
$0 |
90 |
$0.8 |
-$17.2 |
0.7 |
0.4 |
| IMMUNE RESPONSE CORP |
$1.35 |
38% |
-38% |
$27 |
$1 |
$25 |
$3 |
129 |
$0.2 |
-$22.0 |
0.1 |
0.1 |
| INTERMUNE |
$18.62 |
49% |
-30% |
$590 |
$343 |
$247 |
$150 |
210 |
$1.2 |
-$39.0 |
8.8 |
1.2 |
| INTRABIOTICS |
$0.22 |
4% |
-95% |
$1 |
$35 |
-$35 |
$4 |
31 |
-$1.1 |
-$45.1 |
0.8 |
0.0 |
| MEDIMMUNE |
$34.81 |
96% |
4% |
$8,755 |
$527 |
$8,229 |
$218 |
1505 |
$5.5 |
na |
na |
3.3 |
| NABI BIOPHARMACEUTICALS |
$6.07 |
80% |
-3% |
$237 |
$44 |
$193 |
$0 |
615 |
$0.3 |
na |
na |
1.4 |
| SIGA TECHNOLOGIES |
$1.71 |
72% |
-27% |
$23 |
$1 |
$22 |
$0 |
12 |
$1.8 |
-$2.5 |
0.4 |
0.7 |
| TRIMERIS |
$41.65 |
73% |
-13% |
$890 |
$61 |
$829 |
$0 |
109 |
$7.6 |
-$72.6 |
0.8 |
3.1 |
| VAXGEN |
$3.47 |
15% |
-62% |
$55 |
$26 |
$29 |
$0 |
80 |
$0.4 |
-$31.0 |
0.8 |
0.4 |
| VICURON |
$11.80 |
80% |
-6% |
$312 |
$62 |
$250 |
$1 |
28 |
$8.9 |
-$52.5 |
1.2 |
1.5 |
| VION PHARMACEUTICALS |
$0.83 |
32% |
-60% |
$24 |
$13 |
$11 |
$0 |
50 |
$0.2 |
-$9.9 |
1.3 |
0.2 |
| VIROLOGIC |
$1.10 |
32% |
-64% |
$31 |
$6 |
$26 |
$0 |
204 |
$0.1 |
-$22.3 |
0.3 |
0.3 |
| VIROPHARMA |
$3.45 |
81% |
-1% |
$89 |
$176 |
-$87 |
$156 |
418 |
-$0.2 |
na |
na |
0.4 |
| XOMA LTD |
$5.09 |
71% |
36% |
$366 |
$36 |
$330 |
$58 |
193 |
$1.7 |
-$49.0 |
0.7 |
0.7 |
| Infection Average |
. |
55% |
-22% |
$696 |
$90 |
$606 |
$47 |
. |
$1.7 |
-$31.3 |
3.1 |
0.9 |
| Infection Median |
. |
60% |
-23% |
$86 |
$31 |
$45 |
$0 |
. |
$0.7 |
-$22.3 |
0.8 |
0.6 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
Close 04/25/03 |
% 52wk High |
% change from 04/30/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| AMYLIN PHARMACEUTICALS |
$17.86 |
94% |
88% |
$1,655 |
$180 |
$1,474 |
$0 |
150 |
$9.8 |
-$125.2 |
1.4 |
3.1 |
| BIOMARIN PHARMACEUTICAL |
$12.06 |
95% |
100% |
$650 |
$79 |
$571 |
$0 |
216 |
$2.6 |
-$77.3 |
1.0 |
2.0 |
| BIO-TECHNOLOGY GENERAL CORP |
$3.08 |
49% |
-37% |
$181 |
$20 |
$161 |
$14 |
378 |
$0.4 |
na |
na |
0.8 |
| INSMED INC |
$1.07 |
36% |
-61% |
$36 |
$0 |
$35 |
$0 |
2 |
$17.7 |
-$2.2 |
0.0 |
21.0 |
| KERYX BIOPHARMACEUTICALS |
$1.10 |
34% |
-66% |
$22 |
$27 |
-$5 |
$0 |
63 |
-$0.1 |
-$12.1 |
2.2 |
0.3 |
| NPS PHARMACEUTICALS |
$18.40 |
56% |
-38% |
$647 |
$158 |
$489 |
$0 |
146 |
$3.3 |
-$73.1 |
2.2 |
1.7 |
| VIVUS |
$4.19 |
52% |
-33% |
$138 |
$24 |
$115 |
$0 |
119 |
$1.0 |
-$6.6 |
3.6 |
1.0 |
| ZONAGEN |
$1.55 |
38% |
6% |
$18 |
$27 |
-$10 |
$0 |
10 |
-$1.0 |
na |
na |
0.2 |
| Metabolic Average |
. |
57% |
-5% |
$418 |
$64 |
$354 |
$2 |
. |
$4.2 |
-$49.4 |
1.7 |
3.8 |
| Metabolic Median |
. |
52% |
-33% |
$138 |
$27 |
$115 |
$0 |
. |
$1.0 |
-$12.1 |
1.4 |
1.0 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
Close 04/25/03 |
% 52wk High |
% change from 04/30/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| BIOPURE CORP |
$3.59 |
40% |
-60% |
$111 |
$20 |
$91 |
$10 |
249 |
$0.4 |
-$43.1 |
0.5 |
0.3 |
| BIORELIANCE CORP |
$18.85 |
67% |
-30% |
$160 |
$36 |
$124 |
$11 |
556 |
$0.2 |
na |
na |
2.9 |
| BIOTIME |
$1.79 |
59% |
-38% |
$24 |
$2 |
$22 |
$2 |
12 |
$1.9 |
-$2.3 |
0.8 |
0.7 |
| CERUS |
$8.40 |
16% |
-84% |
$134 |
$64 |
$70 |
$0 |
158 |
$0.4 |
-$63.1 |
1.0 |
0.5 |
| COLLAGENEX PHARMACEUTICALS |
$9.25 |
82% |
-5% |
$106 |
$5 |
$100 |
$0 |
155 |
$0.6 |
na |
na |
1.3 |
| COLUMBIA LABORATORIES |
$4.09 |
68% |
-9% |
$145 |
$4 |
$141 |
$10 |
19 |
$7.4 |
-$7.5 |
0.6 |
1.1 |
| CURIS |
$2.20 |
68% |
57% |
$70 |
$31 |
$38 |
$7 |
64 |
$0.6 |
-$82.0 |
0.4 |
0.1 |
| CYANOTECH CORP |
$0.52 |
44% |
-50% |
$10 |
$1 |
$9 |
$4 |
58 |
$0.2 |
-$0.7 |
0.9 |
0.4 |
| CYTRX CORP |
$1.60 |
95% |
58% |
$34 |
$2 |
$32 |
$0 |
5 |
$6.5 |
-$9.9 |
0.2 |
0.4 |
| DISCOVERY LABORATORIES |
$2.81 |
87% |
-12% |
$92 |
$11 |
$81 |
$0 |
50 |
$1.6 |
-$18.1 |
0.6 |
1.2 |
| INSITE VISION |
$0.63 |
29% |
-67% |
$16 |
$4 |
$12 |
$0 |
39 |
$0.3 |
-$12.4 |
0.3 |
0.1 |
| INSPIRE PHARMACEUTICALS |
$13.97 |
85% |
348% |
$362 |
$31 |
$331 |
$0 |
54 |
$6.1 |
-$34.1 |
0.9 |
2.9 |
| INTEGRA LIFESCIENCES |
$26.30 |
100% |
35% |
$719 |
$99 |
$620 |
$0 |
760 |
$0.8 |
na |
na |
2.5 |
| NORTHFIELD LABORATORIES |
$5.60 |
63% |
-21% |
$80 |
$12 |
$68 |
$0 |
60 |
$1.1 |
-$12.6 |
1.0 |
0.7 |
| OSTEOTECH |
$8.39 |
74% |
5% |
$143 |
$19 |
$124 |
$17 |
365 |
$0.3 |
na |
na |
2.2 |
| PALATIN TECHNOLOGIES |
$1.75 |
58% |
-35% |
$50 |
$12 |
$38 |
$0 |
46 |
$0.8 |
-$17.4 |
0.7 |
0.5 |
| PHARMACYCLICS |
$3.65 |
55% |
-41% |
$59 |
$101 |
-$42 |
$0 |
133 |
-$0.3 |
-$27.4 |
3.7 |
0.2 |
| REPLIGEN CORP |
$5.68 |
93% |
93% |
$155 |
$18 |
$138 |
$0 |
40 |
$3.4 |
-$3.1 |
5.7 |
0.9 |
| SALIX PHARMACEUTICALS |
$10.85 |
64% |
-27% |
$232 |
$57 |
$175 |
$0 |
110 |
$1.6 |
-$34.6 |
1.7 |
1.8 |
| SANGSTAT MEDICAL CORP |
$13.05 |
51% |
-44% |
$345 |
$107 |
$238 |
$15 |
263 |
$0.9 |
na |
na |
1.1 |
| TRIPOS |
$5.15 |
19% |
-79% |
$46 |
$10 |
$36 |
$3 |
267 |
$0.1 |
-$3.1 |
3.3 |
1.3 |
| Other Average |
. |
63% |
0% |
$147 |
$31 |
$116 |
$4 |
. |
$1.7 |
-$23.2 |
1.4 |
1.1 |
| Other Median |
. |
66% |
-24% |
$99 |
$15 |
$76 |
$0 |
. |
$0.8 |
-$12.6 |
0.9 |
1.0 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
Close 04/25/03 |
% 52wk High |
% change from 04/30/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| AMGEN |
$63.00 |
98% |
19% |
$81,417 |
$4,664 |
$76,753 |
$3,048 |
10100 |
$7.6 |
na |
na |
4.2 |
| BIOGEN |
$38.51 |
75% |
-11% |
$5,717 |
$828 |
$4,889 |
$39 |
1992 |
$2.5 |
na |
na |
6.9 |
| CHIRON CORP |
$40.62 |
95% |
0% |
$7,595 |
$874 |
$6,721 |
$417 |
4044 |
$1.7 |
na |
na |
3.1 |
| GENENTECH |
$36.40 |
92% |
3% |
$18,658 |
$1,035 |
$17,623 |
$0 |
5252 |
$3.4 |
na |
na |
2.8 |
| GENZYME CORP |
$39.82 |
96% |
-3% |
$8,566 |
$441 |
$8,125 |
$869 |
5600 |
$1.5 |
na |
na |
3.1 |
| GILEAD SCIENCES |
$46.14 |
97% |
48% |
$9,159 |
$942 |
$8,217 |
$595 |
1000 |
$8.2 |
na |
na |
9.6 |
| IDEC PHARMACEUTICALS CORP |
$32.22 |
57% |
-41% |
$4,984 |
$947 |
$4,036 |
$861 |
692 |
$5.8 |
na |
na |
5.5 |
| Revenue-driven Average |
. |
87% |
2% |
$19,442 |
$1,390 |
$18,052 |
$833 |
. |
$4.4 |
na |
na |
5.0 |
| Revenue-driven Average |
. |
95% |
1% |
$8,081 |
$908 |
$7,423 |
$506 |
. |
$2.9 |
$1.0 |
na |
3.7 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
Close 04/25/03 |
% 52wk High |
% change from 04/30/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| DIVERSA |
$10.08 |
83% |
-8% |
$423 |
$164 |
$259 |
$11 |
276 |
$0.9 |
-$26.8 |
6.1 |
1.6 |
| DYAX |
$2.08 |
45% |
-43% |
$41 |
$34 |
$7 |
$16 |
239 |
$0.0 |
-$22.7 |
1.5 |
0.3 |
| ISIS PHARMACEUTICALS |
$4.62 |
36% |
-64% |
$256 |
$292 |
-$36 |
$179 |
434 |
-$0.1 |
-$70.3 |
4.2 |
0.4 |
| LIGAND PHARMACEUTICALS |
$8.00 |
42% |
-49% |
$554 |
$35 |
$519 |
$4 |
351 |
$1.5 |
-$28.2 |
1.3 |
0.8 |
| NEUROGEN CORP |
$3.90 |
30% |
-67% |
$70 |
$84 |
-$14 |
$20 |
200 |
-$0.1 |
-$31.2 |
2.7 |
0.4 |
| ONYX PHARMACEUTICALS |
$8.20 |
89% |
3% |
$195 |
$50 |
$144 |
$5 |
85 |
$1.7 |
-$43.3 |
1.2 |
1.0 |
| REGENERON PHARMACEUTICALS |
$6.44 |
28% |
-69% |
$287 |
$300 |
-$13 |
$200 |
575 |
$0.0 |
-$131.3 |
2.3 |
0.5 |
| TULARIK |
$5.15 |
41% |
-55% |
$284 |
$175 |
$109 |
$9 |
380 |
$0.3 |
-$91.8 |
1.9 |
0.7 |
| Screening Average |
. |
49% |
-44% |
$264 |
$142 |
$122 |
$55 |
. |
$0.5 |
-$55.7 |
2.6 |
0.7 |
| Screening Median |
. |
42% |
-49% |
$256 |
$84 |
$7 |
$11 |
. |
$0.3 |
-$31.2 |
1.9 |
0.7 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Company |
Close 04/25/03 |
% 52wk High |
% change from 04/30/02 |
Market Cap ($M) |
Cash & Mkt. Sec. ($M) |
Tech Value ($M) |
LT Debt plus Convert |
# of Staff |
Tech Value/ Staff ($M) |
Est. Burn Rate ($M) |
Survival Index (Yrs) |
Equity Multiple |
| CARRINGTON LABORATORIES |
$1.24 |
62% |
-37% |
$12 |
$2 |
$10 |
$0 |
181 |
$0.1 |
-$2.2 |
1.1 |
0.2 |
| CELLEGY PHARMACEUTICALS |
$4.14 |
74% |
53% |
$82 |
$5 |
$77 |
$1 |
36 |
$2.1 |
-$6.5 |
0.8 |
0.9 |
| CURATIVE HEALTH SERVICES |
$15.15 |
77% |
8% |
$184 |
$8 |
$177 |
$23 |
302 |
$0.6 |
na |
na |
1.8 |
| GENZYME BIOSURGERY |
$1.76 |
29% |
-68% |
$71 |
na |
na |
na |
na |
na |
na |
na |
na |
| LIFECELL CORP |
$2.50 |
76% |
-16% |
$53 |
$5 |
$48 |
$1 |
138 |
$0.3 |
na |
na |
0.7 |
| LIFECORE BIOMEDICAL |
$3.65 |
31% |
-68% |
$47 |
$1 |
$46 |
$6 |
200 |
$0.2 |
na |
na |
1.0 |
| Wound Average |
. |
58% |
-21% |
$75 |
$4 |
$72 |
$6 |
. |
$0.7 |
-$4.3 |
1.0 |
0.9 |
| Wound Median |
. |
74% |
-16% |
$53 |
$4 |
$47 |
$1 |
. |
$0.5 |
-$2.2 |
1.0 |
0.9 |
| |
. |
|
|
|
|
|
|
. |
|
|
|
|
| Grand Average |
. |
57% |
-26% |
$823 |
$136 |
$710 |
$55 |
. |
$1.3 |
-$38.6 |
3.1 |
1.9 |
| Grand Median |
. |
57% |
-34% |
$131 |
$43 |
$77 |
$0 |
. |
$0.5 |
-$26.2 |
1.6 |
0.8 |
originally published 05/06/2003 |